1

Curriculum Vitae for Academic Promotion

The Johns Hopkins University School of Medicine

(signature)

Gregory J. Riggins, M.D., Ph.D.

DEMOGRAPHIC INFORMATION

Current Appointments

2008-present Professor of Neurosurgery and Oncology, Johns Hopkins University School

of Medicine, Baltimore, Maryland

2004-present Inaugural Recipient of the Irving J. Sherman Research Professorship in

Neurosurgery Research, Johns Hopkins University

2006-present Director, Division of Neurosurgery Research, Johns Hopkins University

School of Medicine, Baltimore, Maryland

Personal Data

Address:

Johns Hopkins University

CRB II, Rm. 257

1550 Orleans Street

Baltimore, MD 21231

Education and Training

Undergraduate Degree

1982 B.Chem.E. University of Delaware, Newark, DE Chemical Engineering

Doctoral/Graduate Degrees

1984 M.S. Penn State University, College Park, PA. Biomedical Engineering

1994 M.D. Emory University, Atlanta, GA Medicine

1994 Ph.D. Emory University, Atlanta, GA Human Genetics

2

Medical Scientist Training Program

1989-1993 Emory University, Atlanta, GA

Laboratory of Stephen T. Warren. Research achievements include genetic

mapping and participation in the cloning of the gene responsible for Fragile X

mental retardation syndrome (FMR-1) as well as research on trinucleotide repeats

and their role in human neurological disease.

Postdoctoral Research Fellowship

1994-1997 Johns Hopkins Oncology Center, Baltimore, MD

Laboratory of Bert Vogelstein & Ken Kinzler, Molecular Genetics Laboratory.

Primary achievements include the cloning of 5 novel human signal-transduction

genes in the TGF- pathway, and demonstrated that SMAD2 acts as a tumor

suppressor in colon cancer.

Professional Experience

1997-2002 Assistant Professor, Duke University Medical Center, Durham, NC

Assistant Professor of Pathology, Molecular Genetics & Microbiology at Duke

University. Built and established a brain cancer genomics research laboratory to

find genes involved in brain cancer. Other primary achievements include the

establishment of the gene expression resources for the Cancer Genome Anatomy

Project.

2002-2003 Associate Professor (with Tenure), Duke University Medical Center, Durham, NC

Associate Professor of Pathology and Assistant Professor of Genetics at Duke

University Medical Center. Academic achievements reviewed by internal board

and external reviewers resulting in tenure as associate professor awarded in 2002.

2003-2004 Visiting Associate Professor of Neurosurgery Johns Hopkins University School

of Medicine, Baltimore, MD

RESEARCH ACTIVITIES

Publications

(All citation numbers are from Thomson ISI Web of Science®, on Feb. 26, 2008. Current field

ranking for Riggins GJ in clinical medicine is based on 138.8 citations per year from 29

evaluated clinical medicine papers with a total of 4,026 citations yielding a ranking for

citations/year at 1,418 of 15,775 published clinical scientists.)

3

Publish or Perish Query: Riggins GJ from 1984 to 2012: all

Summary:

Papers: 117 Cites/paper: 116.13 h-index: 40 AWCR: 1372.98

Citations: 13587 Cites/author: 2872.69 g-index: 116 AW-index: 37.05

Years: 29 Papers/author: 33.57 hc-index: 31 AWCRpA: 287.10

Cites/year: 468.52 Authors/paper: 4.03 hI-index: 8.79 e-index: 106.52

hI,norm: 25 hm-index: 13.48

Quad Search Query

Scientific Search. Displaying 1-100 of 100 results for query: Gregory J Riggins (4.22 sec)

H-INDEX (Hirsch Number): 40. Egghe's G-INDEX: 100

Maximum Cites: 1751

Total Cites: 13045, Total Articles: 100

Cites/Paper: 130.45

Peer Reviewed

1. Lee SJ, Denn MM, Crochet MJ, Metzner AB, and Riggins GJ: Compressive flow

between parallel disks: Oscillatory behavior of visco-elastic materials under a constant

load. Journal of Non-Newtonian Fluid Mechanics. 1984; 14:301-325. (citations: 33)

2. Verkerk AJMH, Nelson DL, Sutcliffe JS, Victoria MF, Zhang F, Eussen BE, v. Ommen

GJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galljaard H, Caskey CT,

Nelson DL, Oostra BA, and Warren ST: Identification of a gene (FMR-1) containing a

CGG repeat coincident with a breakpoint cluster region exhibiting length variation in

fragile X syndrome. Cell. 1991; 65:905-914. (citations: 1,431)

3. Riggins GJ, Sherman SL, Oostra BA, Feitell D, Sutcliffe JS, Nelson DL, Vanoost BA,

Smits APT, Kuhl D, Caskey CT, and Warren ST: A highly polymorphic dinucleotide

repeat, DXS 548, is tightly linked to the fragile-X site. Cytogenetics and Cell Genetics.

1991; 58:2085.

4. Riggins GJ, Sherman SL, Oostra BA, Sutcliffe JS, Feitell DF, Nelson DL, van Oost BS,

Smits APT, Ramos FJ, Pfendner E, Kuhl DPA, Caskey CT, and Warren ST:

Characterization of a highly polymorphic dinucleotide repeat 150 KB proximal to the

fragile X site. American Journal of Medical Genetics. 1992; 43:237-243. (citations: 63)

5. Riggins GJ, Lokey LK, Chastain JL, Leiner HL, Sherman SL, Wilkinson KD, and

Warren ST: Human genes containing polymorphic trinucleotide repeats. Nature Genetics.

1992; 2:186-191. (citations: 147)

6. Riggins GJ, Lokey LK, and Warren ST: CGG repeat polymorphism at the cHa-ras

oncogene locus. Human Molecular Genetics. 1992; 1:775. (citations: 2)

4

7. Riggins GJ, Sherman SL, Phillips CN, Stock W, Westbrook CA, and Warren ST: CGG-

repeat polymorphism of the BCR gene rules out predisposing alleles leading to the

Philadelphia chromosome. Genes Chromosomal Cancer. 1994; 9:141-144. (citations: 4)

8. Riggins GJ, Zhang F, and Warren ST: Biallelic expression of the BCR gene indicates a

lack of parental imprinting, Nature Genetics. 1994; 6:226. (citations: 26)

9. Riggins GJ, Markowitz S, Wilson JK, Vogelstein B, and Kinzler KW: Absence of

secretory phospholipase A2 gene alterations in human colorectal cancer. Cancer

Research. 1995; 55:5184-5186. (citations: 59)

10. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR,

Willson JKV, Markowitz SD, Kinzler KW, and Vogelstein B: Mad-related genes in the

human. Nature Genetics. 1996; 13:347-349. (citations: 328)

11. Riggins GJ, Kinzler KW, Vogelstein B, and Thiagalingam S: Frequency of Smad gene

mutations in human cancers. Cancer Research . 1997; 57:2578-2580. (citations: 221)

12. Okami K, Wu L, Riggins GJ, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt SA,

Reed AL, Hilgers W, Kern SE, Sidransky D, and Jen J: Analysis of PTEN/MMAC1

alterations in aerodigestive tract tumors. Cancer Research. 1998; 58:509-511. (citations:

137)

13. Zhou S, Buckhaults P, Zawel L, Bunz F, Riggins GJ, Dai J, Kern SE, Kinzler KW, and

Vogelstein B: Targeted deletion of Smad4 shows it is required for transforming growth

factor beta and activin signaling in colorectal cancer cells. Proceedings of the National

Academy of Science. 1998; 95:2412-2416. (citations: 132)

14. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JKV, Markowitz SD, Kinzler KW,

and Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. Nature.

1998; 392:300-303. (citations: 1254)

15. De Wind N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins GJ, van der

Valk M, van't Wout K, and te Riele H: HNPCC-like cancer predisposition in mice

through simultaneous loss of msh3 and msh6 mismatch-repair protein functions. Nature

Genetics. 1999; 23:359-362. (citations: 141)

16. Lal A, Lash AE, Altschul SF, Velculescu V, Zhang L, McLendon RE, Marrra MA,

Prange C, Morin PJ, Polyak K, Papadopoulos N, Vogelstein B, Kinzler KW, Strausberg

RL, and Riggins GJ: A public database for gene expression in human cancers. Cancer

Research. 1999; 59:5403-5407. (citations: 408)

17. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry

GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He T-C, Hermeking H,

Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K,

5

Zawel L, Zhang W, Zhang X, Zhou W, Haluska FG, Jen J, Sukumar S, Landes GM,

Riggins GJ, Vogelstein B, and Kinzler KW: Analysis of human transcriptomes. Nature

Genetics. 1999; 23:387-388. (citations: 633)

18. Lash AE, Tolstoshev CM, Wagner L, Schuler GD, Strausberg RL, Riggins GJ, and

Altschul SF: SAGEmap: A public gene expression resource. Genome Research. 2000;

10:1051-1060. (citations: 225)

19. Loging WT, Lal A, Siu I-M, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD,

Strausberg RL, and Riggins GJ: Identifying potential tumor markers and antigens by

database mining and rapid expression screening. Genome Research. 2000; 10:1393-1402.

(citations: 44)

20. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A,

Riggins GJ, Lengauer C, Vogelstein B, and Kinzler KW: Genes expressed in human

tumor endothelium. Science. 2000; 289:1197-1202. (citations: 662)

21. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR,

Riggins GJ, and Morin PJ: Large-scale serial analysis of gene expression reveals genes

differentially expressed in ovarian cancer. Cancer Research. 2000; 60:6281-6287.

(citations: 193)

22. Caron H, van Schaik B, van der Mee M, Baas F, Riggins GJ, van Sluis P, Hermus M-C,

van Asperen1 R, Boon K, Voûte PA, Heisterkamp S, van Kampen A, and Versteeg R:

The human transcriptome map: Clustering of highly expressed genes in chromosomal

domains. Science. 2001; 291:1289-1292. (citations: 597)

23. Cummings TJ, Hulette CM, Bigner SH, Riggins GJ, and McLendon RE: HAM56-

Immunoreactive macrophages in untreated infiltrating gliomas. Archives of Pathology

and Laboratory Medicine. 2001; 125:637-641. (citations: 4)

24. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins GJ, and Polyak

K: A SAGE (Serial Analysis of Gene Expression) view of breast tumor progression.

Cancer Research. 2001; 61:5697-5702. (citations: 109)

25. Lal A, Peters H, St. Croix B, Haroon ZA, Dewhirst MW, Kaanders JHAM, van der Kogel

AJ, and Riggins GJ: Transcriptional response to hypoxia in human tumors. Journal of

the National Cancer Institute. 2001; 93:1337-1343. (citations: 127)

26. Siu I-M, Lal A, and Riggins GJ: A database for regional gene expression in the human

brain. Brain Research: Gene Expression Patterns. 2001; 1:33-38. (citations: 7)

27. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH, and Riggins

GJ: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor

invasion. Cancer Research. 2002; 62:3335-3339. (citations: 61)

6

28. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H,

Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes

R, Hughes J, Kosmidou V, Menzles A, Mould C, Parker A, Stevens C, Watt S, Hooper S,

Wilson R, Jayatllake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones

K, Maltland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmierl G, Cossu A,

Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow

TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, and Futreal PA:

Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954. (citations:

1,195)

29. Strausberg RL, Camargo AA, Riggins GJ, Schaefer CF, De Souza SJ, Grouse LH, Lal A,

Buetow KH, Boon K, Greenhut SF, and Simpson AJ: An international database and

integrated analysis tools for the study of cancer gene expression. Pharmacogenomics J.

2002; 3:156-164.

30. Boon K, Osório EC, Greenhut SF, Schaefer CF, Shoemaker J, Polyak K, Morin PJ,

Buetow KH, Strausberg RL, De Souza SJ, and Riggins GJ: An anatomy of normal and

malignant gene expression. Proceedings of the National Academy of Science. 2002; 99:

11287-11292. (citations: 134)

31. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson

HF Jr, and Powell SM: Gastric cancers overexpress S100A calcium-binding proteins.

Canc. Res. 2002; 62: 6823-6826. (citations: 158)

32. Jongeneel CV, Iseli C, Stevenson BJ, Riggins GJ, Lal A, Mackay A, Harris RA, O’Hare

MJ, Neville AM, Simpson AJ, and Strausberg RL: Comprehensive sampling of gene

expression in human cell lines with massively parallel signature sequencing. Proc. Natl.

Acad. Sci. USA. 2003; 100: 4702-4705. (citations: 47)

33. Porter D, Lahti-Domenici J, Keshaviah A, Bae Y-K, Argani P, Marks J, Richardson A,

Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, and Polyak K:

Moleclar markers in ductal carcinoma in situ of the breast. Molecular Cancer Research.

2003; 1:362-375. (citations: 72)

34. Siu I-M, Lal A, Blankenship JR, Aldosari N, and Riggins GJ: c-Myc promoter activation

in medulloblastoma. Cancer Res. 2003; 63:4773-6. (citations: 12)

35. Boon K, Edwards JB, Siu I-M, Olschner D, Eberhart CG, Marra MA, Strausberg RL, and

Riggins GJ: Comparison of medulloblastoma and normal neural transcriptomes

identifies a restricted set of activated genes. Oncogene. 2003; 22: 7687-94. (citations: 16)

36. Brentani H., Caballero OL, Camargo AA, da Silva AM, da Silva WA., Jr., Dias Neto E,

Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CE, Kelso J, Nagai MA,

Ojopi EP, Osorio EC, Reis EM, Riggins GJ, Simpson AJ, de Souza S, Stevenson BJ,

7

Strausberg RL, Tajara EH, Verjovski-Almeida S, Acencio ML, Bengtson MH, Bettoni F,

Bodmer WF, Briones MR, Camargo LP, Cavenee W, Cerutti JM, Coelho Andrade LE,

Costa dos Santos PC, Ramos Costa MC, da Silva IT, Estecio MR, Sa Ferreira K, Furnari

FB, Faria M, Jr., Galante PA, Guimaraes GS, Holanda AJ, Kimura ET, Leerkes MR, Lu

X, Maciel RM, Martins EA, Massirer KB, Melo AS, Mestriner CA, Miracca CE, Miranda

LL, Nobrega FG, Oliveira PS, Paquola AC, Pandolfi JR, Campos Pardini MI, Passetti F.,

Quackenbush J, Schnabel B, Sogayar MC, Souza JE, Valentini SR, Zaiats AC, Amaral

EJ, Arnaldi LA, de Araujo AG, de Bessa SA, Bicknell DC, Ribeiro de Camaro ME,

Carraro DM, Carrer H, Carvalho AF, Colin C, Costa F, Curcio C, Guerreiro da Silva ID,

Pereira da Silva N, Dellamano M, El-Dorry H, Espreafico EM, Scattone Ferreira AJ,

Ayres Ferreira C, Fortes MA, Gama AH, Giannella-Neto D, Giannella ML, Giorgi RR,

Goldman GH, Goldman MH, Hackel C, Ho PL, Kimura EM, Kowalski LP, Krieger JE,

Leite LC, Lopes A, Luna AM, Mackay A, Mari SK, Marques AA, Martins WK,

Montagnini A, Mourao Neto M, Nascimento AL, Neville AM, Nobrega MP, O'Hare MJ,

Otsuka AY, Ruas de Melo AI, Paco-Larson ML, Guimaraes Pereira G, Pesquero JB,

Pessoa JG, Rahal P, Rainho CA, Rodrigues V, Rogatto SR, Romano CM, Romeiro JG,

Rossi BM, Rusticci M, Guerra de Sa R, Sant' Anna SC, Sarmazo ML, Silva TC, Soares

FA, Sonati Mde F, de Freitas Sousa J, Queiroz D, Valente V, Vettore AL, Villanova FE,

Zago MA and Zalcberg H. The generation and utilization of a cancer-oriented

representation of the human transcriptome by using expressed sequence tags. Proc Natl

Acad Sci U S A. 2003; 100: 13418-13423. (citations: 30)

37. Weeraratna AT, Becker D, Carr KM, Duray PH, Rosenblatt KP, Yang S, Chen Y, Bittner

M, Strausberg RL, Riggins JG, Wagner U, Kallioniemi OP, Trent JM, Morin PJ and

Meltzer PS. Generation and analysis of melanoma SAGE libraries: SAGE advice on the

melanoma transcriptome. Oncogene. 2004; 23: 2264-2274. (citations: 25)

38. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell

SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, and Velculescu

VE. High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science.

2004; 304 (5670):554. (citations: 335)

39. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J,

and Riggins GJ. A preoperative diagnostic test that distinguishes benign from malignant

thyroid carcinoma based on gene expression. J Clin Invest. 2004; 113:1234-1242.

(citations: 43)

40. Strausberg RL, Simpson AJ, Old L, and Riggins GJ. Oncogenomics and the

development of new cancer therapies. Nature. 2004; 429(6990): 469. (citations: 16)

41. Wang Z , Shen D, Parsons W, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters

BA, van der Heijden MS, Parmigiani G, Yan H, Wang T, Riggins GJ, Powell SM, Willison, JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science. 2004; 304(5674):1164-1166. (citations: 110)

8

42. Georgantas RW III, Tanadve V, Malehorn M, Heimfeld S, Chen C, Carr L, Martinez-Murillo F, Riggins G, Kowalski J, Civin CI. Microarray and Serial Analysis of Gene Expression Analyses Identify Known and Novel Transcripts Overexpressed in Hematopoietic Stem Cells. Cancer Res. 2004; 64: 4434-4441. (citations: 40)

43. Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A,

Riggins G, Anderson S, Vredenburgh J, Proia A, Karris LN. HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors. Clin Cancer Res. 2004; 10(12): 4083. (citations: 15)

44. Boon K, Edwards JB, Eberhart CG, and Riggins GJ. Identification of astrocytoma

associated genes including cell surface markers. BMC Cancer. 2004; 4:39. (citations: 10)

45. Lu J, Lal A, Merriman B, Nelson S, and Riggins GJ. A comparison of gene expression profiles produced by SAGE, long SAGE, and oligonucleotide chips. Genomics. 2004; 84: 631-636. (citations: 18)

46. AP Silva, JE De Souza, PA Galante, GJ Riggins, SJ De Souza, AA Camargo. The

impact of SNPs on the interpretation of SAGE and MPSS experimental Data. Nucleic Acids Res. 2004; 32(20): 6104. (citations: 16)

47. Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ and de Souza SJ. Splicing

factors are differentially expressed in tumors. Genet Mol Res. 2004 Dec 30; 3(4):512-20.

48. Boon K, Eberhart C and Riggins GJ, Genomic amplification of Orthodenticle Homolog 2 (OTX2) in Medulloblastomas. Cancer Research. 2005; 65(3): 703-707. (citations: 12)

49. Cuevas IC, Slocum AL, Jun P, Costello JF, Bollen AW, Riggins GJ, McDermott MW,

and Lal A. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res. 2005; 65:5070-5075. (citations: 14)

50. Perez-Plasencia C, Riggins GJ, Vasquez-Ortiz G, Moreno J, Arreola H, Hidalgo A, Pina-

Sanchez P, and Salcedo M. Characterization of the global profile of genes expressed in cervical epithelium by Serial Analysis of Gene Expression (SAGE). BMC Genomics 2005 Sept 19: 6(1) 130. (citations: 4)

51. Rand V, Huang J, Stockwell T, Ferriera S, Buzko O, Levy S, Busam D, Li K, Edwards

JB, Eberhart C, Murphy KM, Tsiamouri A, Beeson K, Simpson AJ, Venter JC, Riggins GJ, and Strausberg RL. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A. 2005; 102:14344-14349. (citations: 11)

52. Siddiqui AS, Khattra J, Delaney AD, Zhao Y, Astell C, Asano J, Babakaiff R, Barber S,

Beland J, Bohacec S, Brown-John M, Chand S, Charest D, Charters AM, Cullum R, Dhalla N, Featherstone R, Gerhard DS, Hoffman B, Holt RA, Hou J, Kuo BY, Lee LL, Lee S, Leung D, Ma K, Matsuo C, Mayo M, McDonald H, Prabhu AL, Pandoh P, Riggins GJ, de Algara TR, Rupert JL, Smailus D, Stott J, Tsai M, Varhol R, Vrljicak P, Wong D, Wu MK, Xie YY, Yang G, Zhang I, Hirst M, Jones SJ, Helgason CD, Simpson EM, Hoodless PA, and Marra MA. A mouse atlas of gene expression: large-scale digital gene-expression profiles from precisely defined developing C57BL/6J mouse tissues and cells. Proc Natl Acad Sci U S A. 2005; 102(51):18485-90. (citations: 32)

9

53. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S,

Bignell G, Davies H, O'meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G,

Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison

R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A,

Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C,

Varian J, West S, Widaa S, Yates A, Easton DF, Riggins GJ, Roy JE, Levine KK,

Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R. A

Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant

Gliomas after Alkylator Chemotherapy. Cancer Res 15 Apr 2006 66(8): p. 3987.

(citations: 16)

54. Dixit, VD, AT Weeraratna, H Yang, D Bertak, A Cooper-Jenkins, Riggins GJ, CG

Eberhart, and DD Taub. Ghrelin and the growth hormone secretagogue receptor

constitute a novel autocrine pathway in astrocytoma motility. J Biol Chem, 2006.

281(24): p. 16681-90. (citations: 7)

55. Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins

GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a

potential molecular therapeutic target in patients with glioblastoma multiforme. Clin

Cancer Res 2006 12(7): p. 1970. (citations: 5)

56. Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Rui M B

Maciel RM, Hojaij FC, Hollis D, Shoemaker J, Riggins GJ. Diagnosis of Suspicious

Thyroid Nodules Using Four Protein Biomarkers. Clinical Cancer Research. 2006 Jun

1;12:3311-8.

57. Wood LD, Calhoun ES, Silliman N, Ptak J, Szabo S, Powell SM, Riggins GJ, Wang TL,

Yan H, Gazdar A, Kern SE, Pennacchio L, Kinzler KW, Vogelstein B, Velculescu VE.

Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutation,

2006. 27(10): p. 1060-1.

58. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SK, Oba-Shinjo SM, Carlotti

CG, Caballero OL, Simpson AJ, Brock MV, Massion PP, Carson BS, Sr., and Riggins

GJ. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer

Res. 2006; 4:709-714. (citations: 3)

59. Beaty RM, Edwards JB, Boon K, Siu IM, Conway JE, and Riggins GJ. PLXDC1

(TEM7) is identified in a genome-wide expression screen of glioblastoma endothelium. J

Neurooncol. 2007; 81(3):241-8.

60. Sawanyawisuth K, Wongkham C, Pairojkul C, Saeseow OT, Riggins GJ Araki N, and

Wongkham S. Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma. Acta

Oncol. 2007; 46(3): 378-85.

61. Trembath DG, Lal A, Kroll DJ, Oberlies NH, Riggins GJ. A novel small molecule that

selectively inhibits glioblastoma cells expressing EGFRvIII. Mol Can. 2007 Apr 16;6:30

10

62. Cerutti J., Oler G., Michaluart P., Delcelo R., Beaty R., Shoemaker J., and Riggins GJ.

Molecular Profiling of Matched Samples Identifies Biomarkers of Papillary Thyroid

Carcinoma Lymph Node Metastasis. Cancer Research 2007; 67 (16): 7885-92.

63. Avarez H, Corvalan A, Roa JC, Argani P, Edwards J, Beaty R, Feldmann G, Hong SM,

Mullendore M, Roa I, Ibañez L, Pimentel F, Diaz A, Riggins GJ, Maitra A. Serial

analysis of gene expression identifies connective tissue growth factor expression as a

prognostic biomarker in gallbladder cancer. Clin Cancer Res. 2008; 14(9):2631-8.

64. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM. Gene

expression profiling of papillary thyroid carcinoma identifies transcripts correlated with

BRAF mutational status and lymph node metastasis. Clin Can Res. 2008;14(15):4735-42.

65. Siu IM, Bai R, Gallia GL, Edwards JB, Tyler BM, Eberhart CG, Riggins GJ.

Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro

Oncol. 2008; 10 (5):716-24.

66. Camacho CP, Latini FR, Oler G, Hojaij FC, Maciel RM, Riggins GJ, Cerutti JM. Down-

regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium

treatment. Clin Endocrinol (Oxf). 2008 Aug 22

67. Latini FR, Hemerly JP, Oler G, Riggins GJ, Cerutti JM. Re-expression of ABI3-binding

protein suppresses thyroid tumor growth by promoting senescence and inhibiting

invasion. Endocr Relat Cancer. 2008; 15(3):787-799.

68. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H,

Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky

Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK,

Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G,

Vogelstein B, Velculescu VE, KInzler KW. An Integrated Genomic Analysis of Human

Glioblastoma Multiform. Science 2008; 26: 321 (5897) 1807-12.

69. Rand V, Prebble E, Ridley L, Howard M, Wei W, Brundler MA, Fee BE, Riggins GJ,

Coyle B, Grundy RG. Investigation of chromosome 1q reveals differential expression of

members of the S100 family in clinical subgroups of intracranial paediatric ependymoma.

Br J Cancer 2008; 99(7):1136-43.

70. Yi JM, Tsai HC, Glockner SC, Lin S. Ohm JE, Easwaran H, James CD, Costello JF,

Riggins GJ , Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE,

Baylin SB. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.

Cancer Res. 2008; 68(19):8094-103.

71. Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, Vescovi AL, Brem H, Riggins GJ.

Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol

Cancer Ther. 2009; 8(2):386-93.

11

72. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle

I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW,

Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 Mutations in Gliomas. N Engl

J Med. 2009; 360(8):765-773.

73. Loilome W, Joshi AD, ap Rhys CM, Piccirillo S, Angelo VL, Gallia GL, Riggins GJ.

Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor

pathway signaling. J Neurooncol. 2009; 94(3):359-66.

74. Duncan CG, Leary RJ, Lin JC, Cummins J, Di C, Schaefer CF, Wang TL, Riggins GJ,

Edwards J, Bigner D, Kopelovich L, Vogelstein B, Kinzler KW, Velculescu VE, Yan H.

Identification of microbial DNA in human cancer. BMC Med Genomics. 2009; May 8

2:22.

75. Rao SK, Edwards J, Joshi AD, Siu IM, Riggins GJ. A survey of glioblastoma genomic

amplifications and deletions. J Neurooncol. 2010; 96(2):169-79.

76. Bai R, Siu IM, Tyler BM, Staedtke V, Gallia GL, Riggins GJ. Evaluation of retinoic acid

therapy for OTX2-positive medulloblastomas. Neuro Oncol. 2010; 12(7):655-63.

77. Siu IM, Tyler BM, Chen JX, Eberhart CG, Thomale UW, Olivi A, Jallo GI, Riggins GJ,

Gallia GL. Establishment of a human glioblastoma stemlike brainstem rodent tumor

model. J Neurosurg Pediatr. 2010; 6(1):92-7.

78. Kuan CT, Wakiya K, Herndon JE 2nd, Lipp ES, Pegram CN, Riggins GJ, Rasheed A,

Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for

human glioblastoma multiforme immunotherapy. BMC Cancer. 2010; Sep 1(10):468.

79. Alvarez H, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G,

Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P,

Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey

A, Maitra A. The Axl receptor tyrosine kinase is an adverse prognostic factor and and a

therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther. 2010; Nov 4 10(10).

80. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T,

Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ. Inhibition of glutaminase

preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010; Nov

15, 70(22):8981-7. PMC3058858.

81. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J,

Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR,

Gerhard DS, Fults DW, Vandenberg S, Berger MS, Marie SK, Shinjo SM, Clara C,

Phillips PC, Minturn JE, Biegel JA, Judkins AR, Resnick AC, Storm PB, Curran T, He

Y, Rasheed BA, Friedman HS, Keir ST, McLendon R, Northcott PA, Taylor MD, Burger

PC, Riggins GJ, Karchin R, Parmigiani G, Bigner DD, Yan H, Papadopoulos N,

12

Vogelstein B, Kinzler KW, Velculescu VE. The Genetic Landscape of the Childhood

Cancer Medulloblastoma. Science. 2010; Jan 28; 331(6016):435-9. PMC3110744

82. Cerutti JM, Oler G, Delcelo R, Gerardt R, Michaluart P Jr, de Souza SJ, Galante PA,

Huang P, Riggins GJ. PVALB, a New Hurthle Adenoma Diagnostic Marker Identified

through Gene Expression. J Clin Endocrinol Metab. 2011; Jan 96(1):E151-60.

83. Loilome W, Juntana S, Namwat N, Bhudhisawasdi V, Puapairoj A, Sripa B, Miwa M,

Saya H, Riggins GJ, Yongvanit P. PRKAR1A is over-expressed and represents a

possible therapeutic target in human cholangiocarcinoma. Int J Cancer. 2011; (129):33-

44.

84. Latini FR, Hemerly JP, Freitas BC, Oler G, Riggins GJ, Cerutti JM. ABI3 ectopic

expression reduces in vitro and in vivo cell growth properties while inducing senescence.

BMC Cancer. 2011; 11(1):11.

85. Binder ZA, Johnson MW, Joshi A, Hann CL, Griffin CA, Olivi A, Riggins GJ, Gallia

GL. Glioblastoma multiforme in the Muir-Torre syndrome. Clin Neurol Neurosurg.

2011; (113):411-415.

86. Joshi AD, Parsons DW, Velculescu VE, Riggins GJ. Sodium ion channel mutations in

glioblastoma patients correlate with shorter survival. Mol Cancer. 2011; 11;10(1):17.

87. Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss CA, Cheong I, Holdhoff M,

Kato Y, Pomper MG, Riggins GJ, Kinzler KW, Diaz LA Jr, Vogelstein B, Zhou S. A

robust approach to enhance tumor-selective accumulation of nanoparticles. Oncotarget.

2011; 2(1-2):59-68. PMC3069713

88. Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: Drug discovery

and therapies. Trends Mol Med. 2011; 17(6):301-312.

89. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez

FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H,

Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban

RH, Maitra A, Papadopoulos N, Meeker AK. Altered telomeres in tumors with ATRX

and DAXX mutations. Science. 2011; 333(6041):425. PMC3174141

90. Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic Mebendazole

Shows Survival Benefit in 2 Preclinical Models of Glioblastoma Multiforme. Neuro

Oncol. 2011; 13(9):974-82. PMC3158014.

91. McDowell KA, Riggins GJ, Gallia GL. Targeting the AKT Pathway in Glioblastoma.

Curr Pharm Des. 2011; 17(23):2411-20.

92. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood, LD, Hruban RH, Rodriguez FJ,

Cahill DP, McLendon R, Riggins GJ, Velculescu VE, Oba-Shinjo SM, Marie SK,

Vogelstein B, Bigner DD, Yan H, Papadopoulos N, Kinzler KW. Mutations in CIC and

13

FUBP1 Contribute to Human Oligodendroglioma. Science. 2011; August 4. [Epub ahead

of print]

93. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or

PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells.

Oncotarget. 2011; 2(11):833-49. PMC3260001

94. Siu IM, Salmasi V, Orr BA, Zhao Q, Binder ZA, Tran C, Ishii M, Riggins GJ, Hann CL,

Gallia GL. Establishment and characterization of a primary human Chordoma xenograft

model. J Neurosurg. 2012; 116(4):801-9.

95. Parat MO, Riggins GJ. Caveolin-1, caveolae, and glioblastoma. Neuro Oncol. 2012;

14(6):679-88. PMC3367849

96. Baia GS, Caballero OL, Orr BA, Lal A, Ho JS, Cowdrey C, Tihan T, Mawrin C, Riggins

GJ. Yes-Associated Protein 1 Is Activated and Functions as an Oncogene in

Meningiomas. Mol Cancer Res. 2012 May 22. [Epub ahead of print]

97. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ,

Rosemberg S, Oba-Shinjo SM, Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C,

Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P,

McLendon R, Bigner DD, Vogelstein BK, Meeker AK, Kinzler KW, Papadopoulos N,

Diaz LA, Yan H. Frequent ATRX, CIC, and FUBP1 mutations refine the classification of

malignant gliomas. Oncotarget. 2012 Aug 3. [Epub ahead of print]

Review Articles

98. Lal A, Siu I-M, and Riggins GJ: Serial analysis of gene expression: Probing

transcriptomes for molecular targets. Current Opinion in Molecular Therapeutics. 1999;

1:720-726.

99. Riggins GJ: Using serial analysis of gene expression to identify tumor markers and

antigens. Disease Markers. 2001; 17:41-48.

100. Polyak K and Riggins GJ: Gene discovery using the serial analysis of gene expression

technique: Implications for cancer research. Journal of Clinical Oncology. 2001;

19:2948-2958. (citations: 63)

101. Riggins GJ and Strausberg RL: Genome and genetic resources from the Cancer

Genome Anatomy Project. Human Molecular Genetics. 2001; 10:663-667. (citations: 36)

102. Cerutti JM, Riggins GJ, and De Souza SJ: What can digital transcript profiling reveal

about human cancers? Braz. J. Med. Biol. 2003; 36: 975-985.

14

103. Borodovsky A, Seltzer MJ, Riggins GJ. Altered Cancer Metabolism in Gliomas with

Mutant IDH1 or IDH2. Curr Opin Oncol. 2012; 24(1):83-9.

Patents

1. Vogelstein B, Kinzler, KW, Riggins GJ, and Thiagalingam, S., Mad-related genes in

the human. U.S. Patent No. 6,255,464. Issued July 3, 2001.

2. Riggins GJ, Loging, WT and Lal L, Four Genetic Tumor Markers Specific for

Glioblastoma. US Patent No. 7,115,625. Issued October 3, 2006

3. Riggins GJ and Lal A., Genes that Respond to Hypoxia. US and International Patent

Application Serial No. 10/465,572

4. Riggins GJ and Cerutti J., Diagnostic Markers for Thyroid Cancer, Provisional

Application Serial No. 11/100,640

5. Riggins GJ and Trembath D, A Novel Small Molecule Specific for Cancer Cells with

an activated EGFR pathway, provisional patent application.

6. Herosian A, Wagner E, and Riggins GJ., Medulloblastoma Genes as Targets for

Diagnosis and Therapeutics, Provisional Application Serial Number 61/411,332.

7. Riggins GJ, Seltzer MJ, Tsukamoto T, Dang CV. Use of Chemical Inhibitors of

Glutaminase Slow Growth of IDH1Mutant Tumors By Depriving Cancer Cells of α-

ketoglutarate.

8. Vogelstein B, Kinzler KW, Parsons DW, Zhang X, Lin CH, Leary RJ, Angenendt P,

Velculescu V, Parmigiani G, Karchin R, Jones S, Yan H, Bigner D, Kuan CT, Riggins

GJ. Genetic Alterations in isocitrate dehydrogenase and other genes in malignant

glioma. Japanese Patent Application No. 2011-526180.

Extramural Sponsorship

Current Research Support

7/29/05- 8/1/2015 Ludwig Center for Cancer Genetics and Therapeutics at the Kimmel

Cancer Center

The Virginia and Daniel K. Ludwig Fund

Current Year $180,000 (directs to Riggins lab) / Total Direct: N/A

Vogelstein & Kinzler (Co-Directors)

Role: Co-investigator 1.2 Cal. Months

The major goal of this center is to identify genetic alterations in colon and brain cancers, and

to develop molecular therapies for these cancers. The center is endowed as a gift to JHU.

01/01/2010-12/31/14 Ludwig Cancer Collaborative Group

Ludwig Institute for Cancer Research

15

LICR-Riggins (PI) 3 Cal. Months

Current Year $271,819 / Total Direct: $1,217,106

The goal of this initiative is to expand our collaborative translational cancer research with the

Ludwig Institute for Cancer Research, and the Ludwig Cancer at Johns Hopkins. The scientific

and medical goal of this collaboration is to more rapidly bring cancer therapies to trial.

12/15/2010-12/14/2013 Pre-Clinical Testing of Bacteriolytic Therapy for Glioblastoma

Voices Against Brain Cancer

VABC-Riggins (PI) 0.24 Cal. Months

Current Year $45,884 / Total Direct: $142,949

Our goal is to use Clostridium novyi-NT (C. novyi-NT), a genetically modified spore-forming

anaerobic bacterium safely for the treatment of glioblastoma multiforme (GBM).

01/01/2011-12/31/2015 Hilton-Ludwig Cancer Prevention Initiative

Ludwig Institute for Cancer Research

LICR-Riggins (PI) 3 Cal. Months

Current Year $133,691 / Total Direct: $688,455

This grant will enable the participants to increase the capacity to develop and test the

effectiveness of early detection methods that could benefit human health and cancer patients

worldwide. LICR is the coordinator of this project and is responsible for the overall project

management.

01/01/2011–12/30/2011 Phase II Study Mebendazole in Patients with Recurrent

Glioblastoma

A Brain Cancer Cure

ABC² – Riggins (PI) 0.6 Cal. Months

Current Year/Total Direct: $158,459

The goal of this project is to evaluate the efficacy of mebendazole in adult patients with recurrent

malignant gliomas in combination with focal irradiation and approved chemotherapies. We will

test other anti-parasitic drugs in the benzimidazole class, and confirm all results in two animal

models.

04/01/2011 – 3/31/2013 Novel Therapeutic Agents for Gliomas with IDH Mutations

NIH 1R21NS074151-01 Tsukamoto (PI) .48 Cal. Months

NIH/NINDS

Current Year $150,000/Total Direct $300,000

The major goals of this project are to identify new glutaminase inhibitors with more drug-like

molecular properties which can serve as therapeutic prototypes for the treatment of gliomas with

IDH mutations.

Role: Co-PI

11/1/2011 – 11/1/2012 Evaluation of OTX2 as a Molecular Target for Medulloblastoma

Children’s Cancer Foundation- Riggins (PI) 0.6 Cal. Months

Total Direct: $74,081

The specific aims of this project are to test several thousand known drugs to determine if any can

be used to induce differentiation in medulloblastomas.

16

Pending Research Support

12/1/2012 – 11/30/2017 Optimization of an Approved Benzimidazole for Glioblastoma

Therapy

PA-11-260

NIH-Riggins (PI) 3.6 Cal. Months

Total Direct: $1,250,000

The goal of this project is to better learn how to use benzimidazoles in combination therapy for

treating glioblastoma. We propose to optimize drug combinations, better understand the potential

resistance mechanisms, and improve delivery.

9/1/2012 – 8/31/2017 Small Molecule Activators of Procaspases as Anti-Cancer Agents

PA-11-260

NIH (Hergenrother) 0.24 Cal. Months

Total Direct: $125,000

This is a sub-grant which involves In vitro testing of Pac-1 derivatives in glioblastoma (GBM)

cell lines and In vivo testing of Pac-1 derivatives in intracranial GBM xenograft and syngeneic

models.

Role: Co-Investigator

Training Grant Participation

5 T32 CA009574-21(S. Grossman)

NIH/NCI Inst. Nat'l Research Service Award

"Research Training in Neuro-Oncology"

Goal: To train neurosurgeons, radiation therapists, medical and pediatric oncologists, and

neurologists for academic careers in neuro-oncology.

Role: Participating Faculty

5T32CA121937-03 (Bunz)

NIH/NCI

“Laboratory Training in Radiation Oncology”

Goal: to train postdoctoral scientists and physicians preparing for careers in academic radiation

oncology.

Role: Co-investigator

Previous Research Support

12/15/1997-12/15/2000 Molecular Genetics of Medulloblastoma Formation

97-51 MMCR

James S. McDonnell Foundation

Total Direct: $375,000

Riggins (PI)

17

The major career goals stated in this young investigator award are to establish a

comprehensive program in brain tumor molecular biology, by establishing a collection of

tumor samples and cell lines, and supporting efforts for gene hunting, gene expression

analysis and analysis of growth regulatory pathways. Four different publications were

supported from this grant.

4/1/1998-4/30/2003 SAGE Analysis of Multiple Tumors for CGAP

NIH 98X- S146A

NIH- Cancer Genome Anatomy Project

Total Direct: $1,369,069

Riggins (PI)

The major goal of this project was to create public gene expression resource for the National

Cancer Institute and the NINDS, under the direction of the Cancer Genome Anatomy Project

(CGAP). SAGE was used to profile and post at the NCI and NCBI expression profiles of major

cancers and normal tissues.

7/1/1998-6/30/2000 Analysis of the Sonic Hedgehog Pathway and its Downstream

Targets

PBTFUS-1998

Pediatric Brain Tumor Foundation

Total Direct: $70,000

Riggins (PI)

The major goal of this project was to locate genes that are induced or repressed in the Sonic

Hedgehog/Patched pathway using global gene expression analysis. This grant was used to

support a pediatric oncology fellow to perform a SAGE analysis of the patched pathway and of

pediatric glioblastomas, using the patched knockout mouse.

7/1/1998-6/30/2002 Positional Cloning of Medulloblastoma Tumor Suppressor Genes

Novartis Faculty Scholar Award

Novartis Pharmaceuticals

Total Direct: $250,000

Riggins (PI)

This scholarship supported efforts to locate genes involved in the pediatric brain cancer,

medulloblastoma. Findings from this support were tumor specific antigens for medulloblastoma.

8/29/2000-1/31/2005 A Molecular Classification of Brain Tumors

NIH U01 CA88128-06

NIH- National Cancer Institute

Total Direct Costs: $1,923,547

Riggins (PI)

The major goal of this project is to use comprehensive gene expression technologies to create an

expression-based classification of gliomas and medulloblastomas, and to use expression analysis

to find brain tumor related genes. Tumor samples were assayed using SAGE followed by tissue

microarrays and real-time PCR analysis. This is a cooperative agreement and part of the NCI

Director’s Challenge.

1/1/2001-9/01/2003 Specific Antigen-Targeted Immunotherapy of

18

Medulloblastoma

PBTFUS center grant

Pediatric Brain Tumor Foundation

Total Direct: $1,000,000

Bigner (PI)

Co-investigator

The major goal of this grant is to evaluate novel genetic targets for the development of

therapeutic antibodies targeted to the major pediatric brain cancer, medulloblastoma. The

Riggins laboratory role was to locate novel tumor-associated antigens.

7/1/2001-6/30/2003 The W.M. Keck Center for Neuro-Oncology Genomics

Keck Center Grant

W.M. Keck Foundation

Total Direct: $1,000,000

Colvin (PI)

Co-investigator

The major goal of this grant is to establish an integrated center for the study of brain cancer

genomics and proteomics. Studies include the molecular classification of tumors and integration

of advance statistics and functional genomics. Our lab performed tissue microarray, real-time

PCR and SAGE analysis.

8/15/2003-8/28/2006 SAGE Analysis of Multiple Tumors for CGAP

NIH- Cancer Genome Anatomy Project, SAIC Frederick

Total Direct Costs: $844,003

Riggins (PI)

The major goal of this project was to provide a public gene expression resource for the National

Cancer Institute’s Cancer Genome Anatomy Project (CGAP). Serial Analysis of Gene

Expression is used to quantify gene expression in normal and malignant human cells. Transcript

counts are posted at the NCBI and NCI’s SAGE Genie web site.

9/1/2003-12/31/2005 Large-Scale Mutation Analysis of Glioblastoma

Ludwig Trust Gift

The Ludwig Trust

Total Direct: $400,000

Riggins (PI)

The major goal of this work is to identify kinase mutations in brain tumors and evaluate these

mutations as potential molecular targets. Dr. Riggins is supported as an affiliate of the Ludwig

Institute.

9/1/2004-8/31/2008 Small Molecule Inhibitors for Pediatric Glioblastomas

CCF

Children’s Cancer Foundation

Total Direct: $305,000

Riggins (PI)

The major goal of this project was to screen for small molecule inhibitors of pediatric gliomas

with PIK3CA mutations using an isogenic cell line strategy and to test the results in an in vivo

19

model. This award is peer reviewed and has been renewed annually for four consecutive years.

4/1/2006-3/31/2009 Tumor Stem Cell-Based Drug Discovery for Adult and Pediatric

Glioma

Brain Tumor Funder’s Collaborative

Total Direct: $510,293

John Lattera, KKI (PI)

Role: Co-investigator

The goal of our subcontracted project was to use stem cell technology to overcome the

deficiencies of the current brain cancer models, and to perform small molecule screens against.

There are three aims; mutation screening of the stem cells, contributing new small molecules we

have in development, and to develop new candidate drugs based on stem cell technology.

6/15/2006-5/31/2011 Preoperative and Follow-up Tests for Thyroid Tumors

NIH 1 R33 CA113461

NIH- National Cancer Institute

Total Direct: $600,000

Riggins (PI)

The goal of this phased innovation award was to further develop an accurate clinical test that

distinguishes benign from malignant thyroid nodules using novel cancer biomarkers.

8/9/2006-4/30/2011 Glioblastoma Genome Project to Locate Molecular Targets

NIH 1 R01 NS052507-01

NIH-National Institute of Neurological Disorders and Stroke

Total Direct: $2,025,668

Riggins (PI)

The goal of this project was to determine which kinase genes are mutated in glioblastoma and to

perform whole genome scans for amplifications and deletions, followed by functional analysis of

the mutated genes.

9/1/2008 – 8/31/2010 Efficacy of c. novyi Therapy in an Orthotopic Glioma Model

Children’s Cancer Foundation

Total Direct: $100,000

Riggins (PI)

The specific aims of this project were to develop, test and image a F98 rat pre-clinical model of

pediatric brain-stem glioblastoma for therapy with c. novyi-NT.

9/12/2008 - 9/11/2010 Genome-wide Sequence Analysis of Human Cancer

28XS268 Velculescu (PI)

SAIC-Frederick

Total Direct: $2,180,557

Co-Investigator

Major Goals: The specific aims of this project were to optimize approaches for somatic mutation

detection using Sanger and next generation sequencing methods and to apply these to examine

the medulloblastoma genome.

20

9/1/2009-8/31/2010 From Targets to Novel Drugs

Bayer Corp- Riggins (PI) .24 Cal. Months

Bayer Schering Pharma

Total Direct: $14,263

The goal of this project was to determine how IDH1 mutation alter brain cancer cell metabolism.

This is a support grant for early stage evaluation of possible drug targets.

10/1/09-6/30/10 Identifying Chemical Inhibitors of Brain Tumors with Mutant IDH1

Ludwig Institute for Cancer Research

LICR-Riggins (PI)

Total Direct: $85,078

The goal of this project was to identify small molecules that successfully inhibit cell growth

when the IDH1 R132H mutation is present.

6/1/2010-5/30/2012 Pre-Clinical Testing of Combination Therapy for Malignant tumors

Arising from Neurofibromas

Congressionally Directed Medical Research

DOD – Riggins (PI) 0.6 Cal. Months

Total Direct: $100,000

The goal of this project is to test combinations of FDA approved drugs on culture and animal

models of Malignant Peripheral Nerve Sheath Tumors (MPNSTs).

04/01/11 - 03/31/12 JHU-Morphotek agreement to evaluate MCCs

Morphotek – Riggins (PI) 0.24 Cal. Months

Total Direct: $50,089

The goal of this work is to evaluate the chlorotoxin 36 aa peptide linked to an Eisai cytotoxic

small molecule, for its efficacy in malignant gliomas.

EDUCATIONAL ACTIVITIES

Editorials

Strausberg RL, and Riggins GJ. Navigating the human transcriptome. Proc Natl Acad Sci U S

A. 2001; 98:11837-11838.

Book Chapters

Riggins GJ and Morin PJ: Chapter 8: “Gene Expression Profiling in Cancer”. In: The Genetic

Basis of Human Cancer, 2nd

edition, (B Vogelstein and K Kinzler, eds.), McGraw Hill Press,

pp. 131-141, 2002.

Boon K and Riggins GJ: Chapter 29: “SAGE as a Strategy to Isolate Cancer-Related Genes”.

In: Tumor Suppressor Genes: Methods and Protocols. Series: Methods in Molecular

Medicine. (WS El-Deiry, M.D., PhD, ed.). Humana Press Inc., pp. 463-479, 2003.

Riggins GJ “Malignant Chapter 102: “The Genetic Origins of Brain Tumors”. In: InYoumans

Textbook of Neurological Surgery-6th

Edition,(Vol. 2 editors, Brem, Sawaya and Chiocca) H.

Richard Winn, editor, (Saunders, Philadelphia, PA) 2011, pp 1133-1140.

21

Other Media

Riggins GJ, Greenhut S, Boon K, Gerhard D, de Souza Sandro, Schaefer C. SAGE Genie,

National Cancer Institute Website, posted by the Cancer Genome Anatomy Project,

http://cgap.nci.nih.gov/SAGE.

Reviews (not peer reviewed)

Riggins GJ: Using serial analysis of gene expression to identify tumor markers and antigens.

In: Basic and Clinical Research on Tumor Markers – Extended Abstracts for the 32nd

International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 2001.

Ed.: Barrett JC, Imai K, Kakizoe T, Shively JE, and Yamaguchi K. pp. 118-123, 2002.

Classroom Teaching:

1998-2000 Molecular Aspects of Disease, Lecturer, Duke PTH 385

1998-2003 Molecular Mechanisms of Oncogenesis, Lecturer, Duke MCB 418

1998-2003 Human Genetics, Lecturer, Duke GEN 232

2000-2003 Current Topics in Cancer Biology, Lecturer, Duke CMB 300

2001-2003 Basic Principles of Pathology, Lecturer, PTH 200, Duke Medical College

2001-2003 Elements of Functional Genomics, Course Co-Organizer, GEN 220, Duke

Graduate School

2002-2006 Medical Biochemistry Course, Invited Lecturer, University of Khon Kaen

2004 EMBO Practical Course, SAGE 2004, Invited Lecturer Academic Medical

Center, Netherlands

2005 Research Update in Neurosciences for Neurosurgeons, Course Lecturer,

Woods Hole, MA

2007- Pathology for Graduate Students, Lecturer, Pathobiology Program, Johns

Hopkins University School of Medicine, Baltimore, MD.

2007 Voyage and Discovery Lecture Series, Invited Speaker, Johns Hopkins

Homewood Campus, Baltimore, MD.

2007 Cellular and Molecular Medicine (CMM) Topics, First Year Graduate Student

Seminar Speaker, Baltimore, MD

Other Teaching Activities:

1998-2003 University Program in Genetics Graduate student preliminary exam committee

1998-2003 Thesis committees for multiple pre-doctoral candidates at Duke University

(Pathology and Genetics Programs)

2001-2006 Thesis advisor and committee member for Royal Golden Jubilee Student,

Kanlayanee Sawanyawisuth University of Khon Kaen, Department of

Biochemistry.

2007- 2010 Thesis committee member, Courtney Goodwin, JHUSOM

2007- Member, Graduate Program in Pathobiology, JHUSOM.

2007- Member, Graduate Program in Cellular and Molecular Medicine, JHUSOM.

2011 - Thesis committee member, Hong Yuen Wong, JHUSOM

2011 - Thesis committee member for Rory Cochran, JHUSOM

2012 - Thesis committee member for Kah Suan Lim, JHUSOM

22

Mentoring:

Post-doctoral and Clinical Fellow Advisor:

Date Name Present Position

1/98-8/03 I-Mei Siu, Ph.D. Instructor, JHUSOM

3/98-8/02 Anita Lal, Ph.D. Associate Director, Product Development and

Clinical Affairs at Pathwork Diagnostics

7/99-11/00 Troy Loging, Ph.D. Research Scientist, Pfizer, Inc

10/99-8/02 Catharina Boon, Ph.D. Life Sciences Technologies Specialist, Independent

Consultant Washington D.C. Metro Area

3/01-8/03 Robert Beaty, Ph.D. Research Associate, JHUSOM

11/00-8/03 Brian Fee, Ph.D. Research Associate, Duke University

7/00-6/02 Christopher Turner, M.D. Instructor, Dana Farber Cancer Institute

7/02-6/03 Yuri Trembath , M.D., Ph.D. Postdoc, Surgical Pathology/Molecular Pathology

program, UNC.

7/02-8/03 Jun Lu, Ph.D. Research Scientist, NIH

3/02-5/04 Tracy-Ann Read, Ph.D. Assistant Professor, Emory University

2/04-12/05 Vikki Rand, Ph.D. Lecturer, Newcastle University

5/04-8/05 Maarten Leerkes, Ph.D. ENCODE project manager at UNC Chapel Hill

7/04-6/07 Gary Gallia, M.D., Ph.D. Associate Professor, Neurosurgery JHUSOM

7/05-6/07 James Conway, M.D. Neurosurgeon, Baltimore Neurosurgery and Spine

Center

11/06-08 Shailaja Kishan-Rao, Ph.D. Postdoc, St. Jude

2/07-01/12 Avadhut Joshi, Ph.D. Research Associate, Riggins Lab, JHUSOM

5/07-03/10 Watcharin Loilome, Ph.D. Instructor, University of Khon Kaen

6/07-12/07 Valéria Muoio, M.D. Pediatric Neurosurgeon, University of São Paulo.

10/07-07/10 Verena Staedtke, M.D., Ph.D. Asst. Resident, Neuro Ped. JHUSOM

02/11-6/11 Meghan Seltzer, Ph.D. Post-Doctoral Fellow - National Biosafety and

Biocontainment Training Program

Undergraduate Research and Independent Study Research Advisor for:

Chad Glazer (medical student Johns Hopkins University), Elizabeth Moody (medical student University of Maryland) Holly Martinson (PhD program in Ecology, U. Boston), and Catherine Robinette, Mellisa Cross (Pre-med student, JHU), Allison Blatz, (Pre-med student, JHU), Sze Yan Janelle Ho (MHS in Epidemiology Candidate), Jessica Emrich (College of Notre Dame Sister Alma McNicholas Women Scientist Program/Johns Hopkins University School of Medicine Women Scientists Initiative) Alex Shimura Yamashita (Ph.D. candidate, Universidade de São Paulo, Kanlayanee Sawanyawisuth, Ph.D., Faculty of Medicine, Khon Kaen University. Dissertation Advisor for: 2007- 2011 Genevieve Weber (Ph.D. program in Pathobiology JHUSOM). 2008-2010 Meghan Seltzer (Ph.D. program in Cellular and Molecular Medicine JHUSOM). 2008- Kelli McDowell (Ph.D. program in Cellular and Molecular Medicine JHUSOM). 2010- Alexandra Borodovsky (Ph.D. program in Cellular and Molecular Medicine JHUSOM).

23

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments:

1997-2003 Medical Scientist Training, UPG, CMB and MCB programs, Graduate student

Interviewer, Duke University

1998-2000 Graduate Admissions Committee, University Program in Genetics

2001 Synergy Summit Committee Member, Duke University Medical Center

2001-2003 Genome Technology Seminar Series Committee Member, Duke Center for

Bioinformatics and Computational Biology

2006- Director of Research, Division of Neurosurgery Research, Johns Hopkins

University School of Medicine.

Editorial Activities:

Referee or reviewer for the following journals: Science, Nature, Nature Biotechnology,

Cancer Research, Neuro-Oncology, The American Journal of Human Genetics, Cell Growth

and Differentiation, Proceedings of the National Academy of Science, Human Molecular

Genetics, Journal of Clinical Oncology.

Advisory Committees, Review Groups

1998- present NIH Cancer Genome Anatomy Project and Tumor Gene Index Steering

Committee

1998- 2003 NIH Brain Tumor Genome Anatomy Project (btGAP) Planning Committee

1999 NIH Scientific Review Group: Innovative Technologies for the Molecular

Analysis of Cancer: SBIR/STTR Initiative & Phased Innovation Award.

Gaithersburg, MD.

1999 NIH Scientific Review Group: Director's Challenge: Towards the

Molecular Characterization of Tumors, RFA CA-98-027, Rockville, MD.

NIH Scientific Review Group: Technologies for Gene Expression

Analysis in the Nervous System, RFA NS99-003. Washington, DC.

1999 NCI Working Group, Tissue Microarray Advisory Board.

2000 NCI & NINDS Brain Tumor Progress Review Group (PRG member)

2001 NIH Mammalian Gene Collection: External Steering Committee Member

2001 Transcriptome International Jamboree, Participant, Ludwig Institute and

Brazilian Genome Project, Sao Paulo, Brazil

2003 NCI Workshop, Comprehensive Molecular Analysis of Human Gliomas and

Medulloblastomas, Bethesda MD

2003 NABTT (New Approaches to Brain Tumor Therapy), Correlative Biology

Committee Co-Chair, Atlanta, GA

2004 NCI Characterization of Cancer in the Cell Working Group Member, Boston,

MA

2004- NCI Working Group & Session Moderator, Exploring Cancer Through

Genomic Sequence Comparisons, Bethesda, MD

24

2004- National Cancer Advisory Board, 2004-Ad Hoc Subcommittee on Biomedical

Technology, Cambridge, MA

2004 NCI Peer Reviewer, Innovations in Cancer Sample Preparation, Rockville, MD

2005 NIH Study Section Ad-Hoc Reviewer, ONC-Q/Basic Mechanisms of Cancer

Therapeutics (BMCT), Bethesda, MD

2006 NIH Study Section, Ad-Hoc Reviewer Cancer Genetics, Washington DC

2007 Program and Research Center Reviewer, Children’s Memorial Research

Center, Falk Brain Tumor Research Center, Chicago, IL

2008 NIH Study Section, Ad-Hoc Reviewer, F09 Oncology Fellowship, Wash. DC

Professional Societies

1992-2004 American Society of Human Genetics, Member

1997- American Association of Cancer Research, Member

1998- The Society for Neuro-Oncology, Member

2000 American Association of Cancer Research, Annual Meeting Abstract Review

Committee, Molecular Biology

Conference Organizer, Session Chair

2000 Co-Organizer. SAGE 2000 Conference: Frontiers in Gene Expression Analysis. A

SAGE Gene Expression Resource for the Cancer Genome Anatomy Project,

Invited Conference Speaker, Baltimore, MD.

2001 Session Organizer and Abstract Review, International Brain Tumor Conference,

Asheville, NC.

2001 Chairperson. SAGE 2001 Conference: Frontiers in Transcriptome Exploration.

Sponsored by Genzyme Molecular Oncology and The National Cancer Institute.

San Diego, CA.

2003 Scientific Committee, SAGE Congress, Amsterdam, The Netherlands.

2004 Organizing Committee, SAGE 2004, Boston, MA.

2006 Co-Organizer and Session Chair. Cancer Genomics and Emerging Technologies,

Boston, MA. Using Genomics to Identify Pathway Targeted Inhibitors for Brain

Cancers.

2008 Scientific Organizing Committee, 7th Annual International Neuro-oncology

Updates, Baltimore, MD.

2012 Session Chair, 19th

International Brain Tumor Research and Therapy Conference,

Niagara Falls, Ontario Canada

RECOGNITION

25

Awards, Honors 1988 Dean's Award for Medical Student Research, Emory University

1989-1992 March of Dimes Predoctoral Fellow

1997-2000 James S. McDonnell Foundation Faculty Scholar Award Program for

Molecular Medicine in Cancer Research, Duke University Medical Center

1998-2000 Novartis Faculty Scholar at Duke University Medical Center

2002 Tenure Awarded (Clinical and Basic Science Track), Duke University

Medical Center, Durham, NC.

2002- Overseas Professor, Department of Biochemistry, Faculty of Medicine, Khon

Kaen University, Thailand

2003-present Recipient of the Irving J. Sherman Research Professorship in Neurosurgery

2007 Invited Lecturer, American Academy of Neurological Surgery

Invited Talks, Panels

1996 Evidence that Smad 2 (JV-18) Acts as a Tumor Suppressor. Cold Spring Harbor,

Cancer Genetics & Tumor Suppressor Genes

1998 Molecular Genetics of Medulloblastoma. The Johns Hopkins Hospital, Baltimore,

Maryland

1998 Serial Analysis of Gene Expression for the Cancer Genome Anatomy Project. NIEHS,

RTP, NC

1998 Advances in Brain Tumor Basic Research, Pediatric Brain Tumor Foundation Annual

Meeting, Asheville, NC

1999 Serial Analysis of Gene Expression of Brain Tumors as part of the Cancer Genome

Anatomy Project. International SAGE Meeting sponsored by the Human Genome

Organization and at the University of Amsterdam, The Netherlands

1999 Expression analysis of multiple tumors for the Cancer Genome Anatomy Project using

Serial Analysis of Gene Expression. Symposium sponsored by the American

Association for Cancer Research, Philadelphia, PA

1999 The Public CGAP/SAGE Database as one Model for Collaborative Expression

Genomics. Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

1999 SAGE and Expression Technologies-Potential Biomarker Application. Symposium on

Biomarkers and Surrogate Endpoints- Advancing Clinical Research and Applications,

NIH and FDA, Bethesda, MD

1999 Genetic and Expression Analysis of Brain Tumors. Emory University Department of

Biochemistry, Atlanta, GA

1999 SAGEmap: A Public Gene Expression Database from The Cancer Genome Anatomy

Project, The 19th

International Symposium of the Sapporo Cancer Seminar

Foundation, Sapporo, Japan

2000 Comprehensive Gene Expression Analysis of Brain Tumors for the Cancer Genome

Anatomy Project, Washington University Cancer Center, St. Louis, MO

26

2000 The BASF Bioresearch Corporation Lecture: The Cancer Genome Anatomy Project's

Molecular Characterization of Brain and Other Tumors, Dana Farber Cancer Institute,

Harvard Medical School, Boston, MA

2000 Molecular Analysis of Medulloblastoma Invited Seminar Speaker, St. Jude Children’s

Research Hospital, Memphis, TN

2000 Identifying Molecular Targets for Cancer Therapeutics using SAGE, Drug Information

Association, Opportunities for Improving The Clinical Development Process,

Philadelphia, PA

2000 Molecular Classification of Brain Tumors Using SAGE, Invited Seminar Speaker,

British Columbia Cancer Agency, Vancouver, BC

2000 Gene Hunting in Cancer using SAGE and the Cancer Genome Anatomy Project,

Invited Seminar Speaker, UNC- Greensboro, Greensboro, NC

2001 Analysis of Seven Million Human Transcripts Identified by SAGE, Invited Speaker,

Brazil International Genome Project, Angra dos Reis, Brazil

2001 Hypoxia Response in Human Cancers, Conference Chair and Invited Speaker, SAGE

2001-Frontiers in Transcriptome Exploration, Coronado, CA

2001 Using Serial Analysis of Gene Expression to Identify Tumor Markers and Antigens,

Invited Speaker, Princess Takamatsu International Symposium, Tokyo, Japan

2002 Finding Cancer Related Genes using SAGE and the Cancer Genome Anatomy Project,

Grand Rounds, Johns Hopkins Oncology Center, Baltimore, MD

2002 Using SAGE to Identify Cancer-Associated Genes: Mutant EGFR Up-Regulates

Effectors of Invasion, Invited Speaker, SIMEC 2002, Rio de Janeiro, Brazil

2002 Using SAGE to Identify Tumor Markers and Antigen: Using new online tools from the

Cancer Genome Anatomy Project, 18th

UICC International Cancer Congress, Oslo,

Norway

2003 An Update on the Cancer Genome Anatomy’s SAGE Project, SAGE Congress: From

Gene Expression to Genome Annotation, Invited Speaker, Amsterdam, The

Netherlands

2003 The Cancer Genome Anatomy Project’s SAGE Genie: A Tool for Cancer Gene

Discovery, Invited Speaker, University of Naples, Italy

2003 Hunting for Cancer-Specific Gene Expression with SAGE Genie, Invited Speaker,

Gordon Research Conference, Andover, NH

2003 Application to Brain Cancer Gene Discovery, Invited Speaker, Genome Science

Center, Vancouver, Canada

2003 SAGE Genie: A NCI sponsored public database with gene expression analysis tools.

Invited Speaker, NCI Workshop Comprehensive Molecular Analysis of Human

Gliomas and Medulloblastomas, Bethesda MD

2003 Identifying Candidate Therapeutic Targets using Large-Scale Gene Expression

Profiling, Invited Speaker, Preuss Foundation, Woodstock, VT

2003 Cancer Genome Anatomy Project’s SAGE Genie: An Online Cancer Gene Discovery

Tool, Invited Speaker, Federal University of Sao Paulo, Brazil

2003 Locating Candidate Brain Cancer Molecular Targets using Genomics, Grand Rounds

Presentation, Department of Neurosurgery, Johns Hopkins, Baltimore, MD

27

2004 An Update on Gliomas: Defining Molecular Targets for Glioblastoma. Invited

Speaker, 4th

International Congress: Genetics and Regeneration in Neuroscience,

Terni, Italy

2004 Genomic Analysis of Brain Cancer. Invited Speaker, TIGR’s GSAC XVI,

Washington, D.C.

2004 Characterizing Cancer Genomes: A Bioinformatics Information Bonanza. Key Note

Lecture, International Conference on Bioinformatics and Computational Biology, Rio

de Janeiro, Brazil

2004 Making the Case for Systematic Analysis of Cancer Genomes, Invited Speaker, 5th

HUGO Pacific Meeting and 6th

Asia Pacific Conference on Human Genetics,

Singapore

2004 National Advanced Technology Initiative for Cancer, Invited Speaker, NCI Systematic

Characterization of Cancer in the Cell Working Group Meeting, Boston, MA

2004 Making the Case for Systematic Analysis of Cancer Genomes, Presentation Ludwig

Institute for Cancer Research, New York, NY

2005 Glioblastoma Bad Boys: The Mutant Kinases, Brain Tumor Seminar Series

Presentation, Johns Hopkins, Baltimore, MD

2005 Brain Cancer Genomics: Locating molecular targets. Invited Speaker, 3rd

Takeo

Wada Cancer Research Symposium, Khon Kaen, Thailand

2005 Locating and Exploiting Molecular Targets in Brain Cancers. Invited seminar speaker,

Department of Biochemistry, University of Khon Kaen, Thailand

2005 Large-Scale Genomic Analysis of Brain Cancers. International Meeting, Updates in

Neuro-Oncology, Arezzo, Italy

2005 Hijacking Developmental Pathways: The Genetic Basis of Medulloblastoma, Grand

Rounds Presentation, Department of Neurosurgery, Johns Hopkins, Baltimore, MD

2005 Molecular Basis of Cancer: Transforming mutations and opportunities for molecular

targeting. Invited Speaker, AO ASIF Spine Tumor Symposium, Baltimore

2006 Identification of Small-Molecules that Target Mutation-Driven Pathway Activation of

Brain Cancers. Invited Speaker, Molecular Medicine Triconference- Pathways

Analysis for Target and Compound Evaluation, San Francisco, CA

2006 First-Step Small Molecule Development for Glioblastomas with RTK Pathway

Activation. Invited Speaker, Brain Tumor Spore Monthly Seminar, University of

California at San Francisco, CA

2006 Identifying Targets and Inhibiting Pathways Activated in Brain Cancer, Invited

Seminar Speaker, Carole and Ray Neag Comprehensive Cancer Center Seminar

Series, University of Connecticut, Farmington, CT

2006 Identifying Molecular Targets and Inhibitory Small Molecules for Brain Cancers,

Invited Speaker, Brain Tumor Center of Excellence, Wake Forest University School of

Medicine, NC.

2006 A High-Throughput Genomics Project for Glioblastoma. Invited Speaker,

International Brain Tumor Research and Therapy Meeting, Napa CA

2006 The Search for Useful EGFR Pathway Inhibitors for Brain Tumors. Invited Speaker,

Ludwig Institute for Cancer Research EGFR Cascade Meeting, San Diego, CA

28

2006 Identifying MolecularTargets and Inhibitory Small Molecules for Brain Cancers.

Invited Lecturer, Federal University of Sao Paulo, Brazil

2006 Identifying New Mutation and Genomic Alterations in Glioblastoma. Activation of

OTX2: An Early Neural Development Pathway in Medulloblastoma. Searching for

new Glioblastoma Small Molecule Targets. Invited Speaker, 5th

Annual Neuro-

Oncology Update, Memphis TN

2006 The Search for EGFR/AKT Pathway Targets and Inhibitors for Glioblastoma. Invited

Speaker, XVIth International Congress of Neuropathology, San Francisco, CA

2006 Using genomics to identify pathway targeted inhibitors for brain cancers. Cancer

Genomics and Emerging Technologies conference, Cambridge, MA

2006 Session Chair: Cancer Therapeutic Targeting and Drug Resistance, Cancer Genomics

and Emerging Technologies (CGET) Conference, Cambridge, MA

2006 Using Genomics to Identify Pathway Targeted Inhibitors for Brain Cancers, Invited

Seminar Speaker, Children’s Memorial Research Center, Chicago, IL

2007 The mutational basis of glioblastoma formation: How much of the story do we know?,

Invited Faculty and Speaker, 2nd International Updates in Neuro-Oncology, Cortona,

Italy.

2007 Keynote Address: Distinguishing Adenoma from Carcinoma in Thyroid Cancers,

Distinguished Faculty, Cancer Proteomics and Molecular Diagnostics World

Congress, Philadelphia, PA.

2007 Dissecting Brain Cancer Genomes to Locate New Molecular Targets, Invited Speaker,

XIX Congreso Mexicano de Cirugia Neurologica, Mexico City, July 12, 2007.

2007 (Moderator) Cellular and Molecular Medicine Graduate Training Program, Fourteenth

Annual Retreat, Baltimore, MD.

2007 The Glioblastoma Genome: Revealing Secrets for Better Therapy, Invited Speaker,

American Academy of Neurological Surgery Meeting, Lake Las Vegas, 2007.

2008 Advances and Challenges in Glioblastoma Targeted Therapy, Neurosurgery Grand

Rounds, Johns Hopkins University, Baltimore, MD.

2008 Advances and Challenges in Glioblastoma Targeted Therapy, Invited Speaker,

Multidisciplinary Perspectives in Brain Tumor Management, Puerto Vallarta, August,

2008.

2008 Does Brain Cancer Genomics Help Us Identify Molecular Targets? Invited Speaker,

Seventh Annual International Neuro-Oncology Updates, Baltimore MD, September

2008

2008 Un Update on JHU Brain Tumor Research: Two Major Breakthroughs. Neurosurgery

Advisory Board Meeting, Johns Hopkins University, Baltimore, MD

2009 Employing Brain Tumor Stem-Like Cells for Drug Testing and Development. Invited

Speaker, Opportunities in Translational Cancer Medicine, San Diego, CA. January

2009

2009 Mutation profiles of glioblastomas: IDH1 and other new insights into brain tumor

biology. Neurosurgery Rounds, Johns Hopkins University, Baltimore, MD. March

2009

2009 The Biology and Genomics of Glioblastomas. Biology of Cancer Lecture Series. Johns

Hopkins University, Baltimore, MD. April, 2009

2009 Johns Hopkins Ludwig Center: Advances in Brain Cancer Research. Ludwig Trustees

Meeting. New York, NY April 2009

29

2009 Creating a controlled anaerobic bacterial infection in Glioblastoma as a means to

enhance therapy, Neurosurgery Grand Rounds, June 25, 2009.

2009 Analysis of the Genome in Brain Cancer - New Molecular Objectives. Invited Speaker

XX Neurosurgery Mexico Congress, Cancun, Mexico. July 2009

2009 The Glioblastoma Genome:Translational Promises and Challenges. Invited Speaker.

Updates in Neuro-Oncology, OSU, Columbus Ohio. September 2009

2009 Strategies for Translating Research to Therapy for GBM. Invited Speaker, Ludwig

GBM Meeting, New York, NY. September 2009

2009 Creating a controlled anaerobic bacterial infection in Glioblastoma as a means to

enhance therapy. Ludwig Clinical Trial Meeting, New York, NY. September 2009

2009 New Approaches to Pre-Clinical Development of Glioblastoma Therapy. Invited

Speaker, Translational Research Conference Johns Hopkins University, Baltimore,

MD. October 2009

2009 New Approaches to Pre-Clinical Development of Glioblastoma Therapy. Invited

Lecturer for Graduate Course GPLS 665, University of Maryland, Baltimore, MD.

October 2009

2009 Mutational Basis of Glioblastomas. Drinks and Data Lecture Series, Department of

Neurooncology, Johns Hopkins University, Baltimore, MD. October 2009

2010 The Brain Cancer Biology and Therapy Laboratory. Presented to Johns Hopkins

International, Baltimore MD. January 15, 2010

2010 Glioblastoma Genomic Amplifications, Deletions and Mutations. Invited Speaker

Comprehending Copy Number Variation/X Gen Congress, San Diego, CA. March 15,

2010.

2010 Preclinical Evaluation of Small Molecule Therapy for GBM. Ludwig Institute for

Cancer Research. NY, NY. March 17, 2010

2010 Ludwig Collaborative Research Group. Inaugural Joint Lab Meeting. Johns Hopkins

University School of Medicine, Baltimore MD. May 4, 2010

2010 Developing New Therapies for Brain Cancer: Highlights of Challenges and Progress.

Representing Hopkins International at the Institute of Caribbean Insurance Risk

Managers Meeting. May 16, 2010

2010 Creating a Meningioma Research Program at Johns Hopkins. Neurosurgery Advisory

Board Meeting. Johns Hopkins University School of Medicine. June 4, 2010

2010 Evaluating New Therapeutic Approaches to Brain Cancer. NIH, National Institute of

Aging, Baltimore, MD. June16, 2010.

2010 Do Genomics Help with Therapy Design for GBMs? Updates in Neuro-Oncology,

Cortona, Italy, July 3rd

, 2010.

2010 The birth of brain tumors: from molecules to cells. 1st. Neurosciences Symposium

Johns Hopkins Hospital & Fundacion Santa Fe de Bogota. August 13, 2010.

2010 Therapy Development based on mutations found in Human Glioblastoma Genomes.

Symposium on Applications of Molecular Markers in Cancer Meeting, Oaxtepec,

Morelos, Mexico. September 2010.

2010 Therapy Development for Glioblastoma Multiforme at the Brain Cancer Biology and

Therapy Laboratory. ABC², Washington DC October 2010

2010 Preclinical Development of Mebendazole as Evidence for Possible Human Trials

against Recurrent Glioblastoma. Ludwig Collaborative Meeting. October 13, 2010.

30

2010 Identifying Molecular Targets in Brain Cancer Genomes. Department of Biomedical

Engineering Institute for Computational Medicine Johns Hopkins University,

Baltimore, MD. October 28, 2010.

2010 Preclinical Evaluation of Small Molecule Therapy for GBM. Johns Hopkins

University Ludwig Collaborative Laboratory, Johns Hopkins University, Baltimore,

MD. December 15, 2010.

2011 Identifying and Testing Molecular Targets for Brain Cancers. Federal University of

Para Belem, Brazil. February 2011

2011 A Therapeutic Strategy for Selective Inhibition of Gliomas and Leukemia with IDH1

and IDH2 Mutations. Neurosurgery Grand Rounds, Johns Hopkins University,

Baltimore, MD February 24, 2011

2011 Preclinical Development of Mebendazole as Evidence for Possible Human Trials

against Recurrent Glioblastoma. Johns Hopkins University Ludwig Collaborative

Laboratory, Johns Hopkins University, Baltimore, MD. March 25, 2011

2011 A Therapeutic Strategy for Selective Inhibition of Gliomas and Leukemia with IDH1

and IDH2 Mutations. HiltonMeeting, Johns Hopkins University, Baltimore, MD. May

9, 2011

2011 A Therapeutic Strategy for Selective Inhibition of Gliomas with IDH1 Mutations.

University of Maryland. Baltimore, MD. June 14, 2011

2011 Genomic and Translational Research for Gastrointestinal Cancers. Seminar for

GastroPará, Belém, Brazil. September 5, 2011.

2011 Investigation of the Anti-Parasitic Drug Mebendazole for Treatment of High Grade

Gliomas. Ludwig Technology Development Meeting, New York, NY. September 7,

2011

2011 Development of the Anti-Parasitic Drug Mebendazole for High Grade Glioma

Therapy. Seminar for Neuro-Oncology Updates Meeting, Nashville, TN. September

16, 2011.

2011 Development of Mebendazole and Approved Drugs to Treat Gliomas. Accelerate Brain

Cancer Cure Annual Meeting, Sausalito, CA. September 30, 2011.

2011 Evaluation of IDH1 and other targets for the Treatment of Malignant Gliomas. MSKCC Brain Cancer Seminar, New York, NY. October 4, 2011

2011 Meningioma Research Program Update. Johns Hopkins Neurosurgery Advisory

Board Meeting. Baltimore, MD. November 4, 2011

2011 Preclinical Development of Small Molecule Therapies for Brain Cancer. NIH Drug

Screening Center Seminar, Bethesda, MD. December 21, 2011.

2012 Preclinical Development of New Therapies for Glioblastoma Multiforme. The

Translational Genomics Research Institute, Phoenix, AZ. February 22, 2012.

2012 Preclinical Development of New Therapies for Glioblastoma Multiforme. Cancer

Targets and Therapeutics/Oncology Partnering Conferences, Las Vegas, NV. February

28, 2012.

2012 Cancer Genomics. Cancer Genomics Class, Belém, Brazil. March 21, 2012

2012 Preclinical Development of New Therapies for Glioblastoma Multiforme. Federal

University of Para, Brazil. March 22, 2012

2012 Session Moderator: Glioblastoma Genomic Alterations and Molecular Targets. 19th

International Brain Tumor Research and Therapy Conference. Niagara Falls, Ontario,

Canada. June 23, 2012.

31